CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 2025
Article content
Company's AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models.
Article content
Article content
MOUNT LAUREL, N.J. — CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago.
Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to existing therapies. Gilteritinib (Xospata ®; Astellas Pharma, peak annual sales projection: $1.5 billion) and Quizartinib (Vanflyta ®; Daiichi Sankyo) are two FDA-approved FLT3 inhibitors, with the former approved only for relapsed/refractory AML and the latter approved only for newly diagnosed AML. Quizartinib does not target TKD resistance mutations, whereas Gilteritinib's efficacy on FLT3-ITD-D835 mutations is limited and it is not effective against the FLT3-ITD-F691 gatekeeper mutation, both of which are very common. Crenolanib (AROG/Pfizer) is an FLT3 inhibitor whose NDA submitted to the FDA does not address the indications above, whose NDA was previously rejected by the FDA, and which binds to FLT3 mutants less tightly than Gilteritinib. Consequently, there is a critical need for next-generation FLT3 inhibitors that can address all of these mutations.
Article content
At ASCO 2025, CCM Biosciences' presentation 'Novel, Potent and Selective Inhibitors Targeting FLT3 for AML Therapy' in the Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant session (Abstract #: 6542, https://www.asco.org/abstracts-presentations/ABSTRACT502974) will report novel FLT3 inhibitors have been identified that can both target FLT3-ITD and potentially overcome mutational resistance to FDA-approved FLT3 inhibitors. These agents are significantly more effective than Gilteritinib and have significant potential clinical applications.
Article content
CCM Biosciences' novel, orally bioavailable FLT3 inhibitors (CCM-405 and CCM-445) are the first drug candidates to overcome both FLT3-ITD juxtamembrane domain and tyrosine kinase domain (TKD) mutational drug resistance (including D835Y, F691L), significantly outperforming the aforementioned current-generation inhibitors both in the absence and presence of resistance mutations. Other reported investigational drug candidates capable of addressing FLT3-ITD resistance mutations either have poor pharmacokinetics, significant off-target binding, or both.
Article content
CCM Biosciences is advancing clinical candidates from its FLT3 inhibitor program to investigational new drug (IND) filing this year for entry into clinical trials for both newly diagnosed FLT3-positive AML and relapsed/refractory FLT3-positive AML. Multiple failures in AML clinical trials from competitors in 2024 present an attractive landscape for clinical trials of these drug candidates.
Article content
The company is actively partnering with biotechnology and pharmaceutical companies for co-development rights in selected countries. CCM Biosciences, a sister company of the global chemical and pharmaceutical services company PMC Group, Inc., is also a Featured Exhibitor at ASCO 2025 — https://asco25.myexpoonline.com/co/ccm-biosciences — and will be showcasing both its drug programs and the state-of-the-art platforms used to discover and develop them.
Article content
About CCM Biosciences
CCM Biosciences is a diversified biotechnology company dedicated to discovering and developing novel drugs, including small molecules, gene therapies, biologics, and nanomedicines within multiple corporate subsidiaries. CCM's patented drug discovery platforms were developed at Chakrabarti Advanced Technology, a privately funded R&D institute founded in 2010 with scientists in the US, France and India and with publications in leading scientific journals including PNAS, Nucleic Acids Research, Physical Review, American Chemical Society journals, Biophysical Society journals, and Nature Publishing Group journals. These platforms are complemented by the contract research, development, and manufacturing organizations (CRDMO) at PMC Group, the sister company of CCM Biosciences and a global chemical and pharmaceutical company with ~$1 billion in annual revenue.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
11 minutes ago
- Globe and Mail
Here's Why Aehr Test Systems Surged Again This Week
Shares in Aehr Test Systems (NASDAQ: AEHR) rose another 15.9% in the week to Friday morning. The move marks another wave of optimism for its potential to diversify away from its core silicon carbide (SiC) wafer-level burn-in (WLBI) test solutions and into new markets such as the gallium nitride (GaN) WLBI market. Why developing new markets matters Not only would diversification help reduce dependence on the SiC WLBI market (where ON Semiconductor is traditionally a major customer for Aehr), it would also move Aehr Test Systems into a GaN market that appears to be building momentum. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » The good news is Aehr disclosed that three of its four customers, each of which represented more than 10% of its revenue in the third quarter, were in artificial intelligence processors and in the GaN WLBI market on its recent earnings call. The latter is pertinent considering that Navitas Semiconductor recently said it had been selected to collaborate with Nvidia to develop GaN and SiC chips for the next-generation data center architecture. The news sent Navitas stock soaring, and this week Navitas also said it had a partnership in place to develop SiC chips with BrightLoop. Navitas and Aehr Test Systems All of which raises the question whether Navitas is one of the customers Aehr's management mentioned recently. Confidentiality agreements preclude disclosure, but at a recent William Blair conference, the moderator referenced the Navitas/Nvidia collaboration when introducing Aehr CEO Gayn Erickson. Erickson didn't deny that Navitas is a customer. That's way short of a strong conclusion that Navitas is a significant Aehr customer, and Sherlock Holmes would blush at the logic, but it's probably what's driving the stock higher this week. Should you invest $1,000 in Aehr Test Systems right now? Before you buy stock in Aehr Test Systems, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Aehr Test Systems wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor 's total average return is789% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025
Globe and Mail
12 minutes ago
- Globe and Mail
Dallas Texas Based SEO Agency Launches 'ChatGPT Embeds' Plugin for Adding Useful Artificial Intelligence to WordPress Websites
"An Automated Blog Post Summary powered by ChatGPT appears in bullet point format at the top of a WordPress blog post about Google's AI Mode. All blog posts on the site now have automated summaries appearing at the top automatically generated by the ChatGPT Embeds WordPress plugin." Joe Youngblood SEO & Digital Marketing Consulting has launched a new WordPress plugin, ChatGPT Embeds, designed with input from clients of the Dallas SEO company. The plugin allows websites to embed pre-built ChatGPT features, including Page Summary, ChatGPT Insights, Automated Summaries, and an Ask ChatGPT button. Designed to boost satisfaction, this tool is part of the agency's advanced WordPress SEO services and reflects its commitment to innovation and client success. Dallas, TX - June 6, 2025 - Joe Youngblood SEO & Digital Marketing Consulting, a Dallas-based search engine optimization agency renowned for its cutting-edge SEO strategies and WordPress SEO expertise, is proud to announce the release of a new proprietary plugin for WordPress powered websites to help them leverage AI for their own success without any coding or programming knowledge required: ChatGPT Embeds. Developed exclusively for agency clients, the ChatGPT Embeds plugin empowers WordPress websites to seamlessly integrate pre-built ChatGPT features directly into their pages using expertly crafted prompts or even custom prompts if desired. Designed to enhance user engagement and increase user satisfaction using dynamic AI-driven content, the plugin currently offers four innovative features: • Page Summary – Instantly generates and displays concise, AI-powered summaries of content for quick user consumption. • ChatGPT Insights – Provides unique insights related to the page topic and data. • Automatic Blog Post Summaries - Creates an automated AI-generated content summary that posts to the top or bottom of all blog posts automatically. • Ask ChatGPT Button – Adds an interactive prompt button that allows site visitors to send a prompt asking about the content of a page directly to ChatGPT. 'Finding innovative ways to integrate artificial intelligence into WordPress websites isn't just the future - it's what users are coming to expect right now,' said Joe Youngblood, founder and lead strategist. 'We built the ChatGPT Embeds plugin to give our clients an immediate edge by combining one of the most powerful AI engines with a seamless and intuitive WordPress integration.' In testing the plugin showed an extremely low incident rate of generative AI hallucinations and surfaced the most important facts in a web document summary over 95% of the time. Meaning websites can trust the summaries and insights being generated are accurate and helpful for their users. The plugin also has built in safety mechanisms and ways for website owners to manually override the automation or remove it from specific documents. SEO friendliness and speed are also built in to this AI embedding plugin using the latest in technical SEO standards to ensure all content generated is automatically optimized for improved rankings and visiblity, and using various techniques to ensure the plugin loads swiftly and does not interfere with or slowdown the website. This plugin is not yet publicly available and is currently offered exclusively to clients of Joe Youngblood SEO & Digital Marketing Consulting as part of their WordPress SEO service packages. ChatGPT Embeds represents the firm's ongoing commitment to innovation in the SEO and artificial intelligence spaces with a focus on improving how all businesses can use the power of AI for their own growth. Clients leveraging the plugin can expect enhanced user satisfaction and improve brand awareness among users who trust and use AI chat systems frequently - positioning their sites ahead of the curve in a rapidly evolving digital landscape. The agency also announced plans to continue working on and improving this technology with feedback from their clients and will ultimately release open source versions of this innovation for the entire WordPress community to benefit from. For more information or to inquire about the ChatGPT Embeds plugin, visit: Media Contact Company Name: Joe Youngblood SEO & Digital Marketing Consulting Contact Person: Joe Youngblood Email: Send Email Phone: 469-607-8460 Address: 16135 Preston Rd. Ste 110A City: Dallas State: Texas Country: United States Website:
CTV News
29 minutes ago
- CTV News
Stablecoins' step toward mainstream could shake up parts of U.S. Treasury market
As stablecoins take a step toward becoming mainstream, some segments of the U.S. Treasury market, notably securities with short-term maturities, could be vulnerable to volatility as they become more closely tied to the world of cryptocurrency. Congress is poised to pass legislation establishing a regulatory framework for stablecoins, expected to help legitimize the dollar-pegged cryptocurrencies which are commonly used by crypto traders to move funds between tokens. Proponents of the bill argue that clear rules will spur further stablecoin activity, and support a growing sector of buyers of short-term U.S. government debt, or T-bills, that are typically considered cash-equivalent securities. But others worry a larger footprint for a relatively new and more volatile industry could in turn spur volatility in the bills market. 'In the event of a sudden loss of confidence, regulatory pressure, or market rumors, this could trigger large-scale liquidations, potentially depressing Treasury prices and disrupting fixed-income markets,' said Cristiano Ventricelli, vice president and senior analyst of digital assets at Moody's Ratings. 'A problem in the stablecoin sector could spill over into broader financial markets, affecting institutions holding similar assets or (that) rely on stablecoin liquidity,' he added. If signed into law, the stablecoin bill would require tokens to be backed by liquid assets - like U.S. dollars and short-term Treasury bills - and monthly disclosures from issuers on the composition of their reserves. That means if stablecoins are expected to grow, issuers will have to purchase more T-bills to back their assets. The bill could be passed by the Senate as early as next week and could eventually increase the amount of U.S. Treasuries held by stablecoin issuers such as Tether and Circle, the latter of which debuted on the NYSE on Thursday. They together hold $166 billion in U.S. Treasuries, according to a report by Bain & Company's financial services practice. The stablecoin market, currently about $247 billion according to crypto data provider CoinGecko, could grow to $2 trillion by 2028 if legislation were to pass, Standard Chartered estimated. U.S. Treasury Secretary Scott Bessent encouraged lawmakers to pass legislation to codify federal rules for stablecoins, arguing that it could lead to a surge in demand for U.S. government debt. Currently, there are about $29 trillion in Treasury securities outstanding, of which $6 trillion are bills. RED FLAGS In an April research note, JP Morgan analysts estimated that stablecoin issuers could become the third-largest buyer of Treasury bills in the coming years. That raises red flags for some, who worry that would lead to closer ties between the crypto ecosystem and the traditional financial world. The Treasury Borrowing Advisory Committee, a group of banks and investors that advise the government on its funding, said in a study in April that growth of the stablecoin market at the expense of bank deposits could reduce banks' demand for U.S. Treasuries, as well as have an impact on credit growth. 'If (stablecoin issuers) have to move those Treasuries quickly, or the market demands that, it could create some credit crunches there,' said Mark Hays, associate director for cryptocurrency and financial technology at Americans for Financial Reform. Hays said this assumes that stablecoins become more widely used after legislation passes. Money market funds, which invest in short-term debt, could be impacted. Money market expert Pete Crane, president of Crane Data, said money funds are watching stablecoin closely but the size of the market would have to become significantly bigger to create concerns over financial stability. 'Treasury bills are normally so short (in maturity) that people don't concern themselves with price movements, but of course in case of a rapid liquidation the price is going to go down,' he said. Issues with stablecoins have not so far been large enough to cause systemic problems but the calculus could shift if federal legislation were to spur widespread adoption. In 2022, a meltdown in the crypto markets sent Tether's stablecoin below its dollar peg, which caused no impact on the Treasury market. At the time, then-U.S. Treasury Secretary Janet Yellen said stablecoins like Tether didn't pose a systemic risk to the financial system because they were too small in scale. In 2023, Circle's USD Coin also lost its dollar peg after the company revealed it held a portion of its reserves at failed Silicon Valley Bank. Circle and Tether declined comment. POTENTIAL UPLIFT TO MARKET Still, some argue that there could be benefits from increasing demand for government debt. 'If we pass stablecoin legislation, dollars will be exported around the world, which will extend the strength of the dollar as the world's reserve currency,' said Matt Hougan, chief investment officer at Bitwise Asset Management, a crypto asset manager. Roger Hallam, global head of rates at Vanguard, said higher demand for short-term government debt instruments could incentivize the Treasury Department to increase T-bill issuance, rather than long-dated debt, to cover its deficit funding need. Yields of long-dated U.S. debt have been rising recently, partly due to concerns over the country's fiscal health. 'You could choose to issue more bills to meet that demand, which would relieve some of the tensions we currently see in the market ... around the scale of future issues and who's going to buy all these bonds,' Hallam said. (Reporting by Hannah Lang and Davide Barbuscia in New York; Editing by Megan Davies and Andrea Ricci)
